-
Courses
Courses
Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
-
University Life
University Life
Each year more than 4,000 choose University of Galway as their University of choice. Find out what life at University of Galway is all about here.
-
About University of Galway
About University of Galway
Since 1845, University of Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
-
Colleges & Schools
Colleges & Schools
University of Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
-
Research & Innovation
Research & Innovation
University of Galway’s vibrant research community take on some of the most pressing challenges of our times.
-
Business & Industry
Guiding Breakthrough Research at University of Galway
We explore and facilitate commercial opportunities for the research community at University of Galway, as well as facilitating industry partnership.
-
Alumni & Friends
Alumni & Friends
There are 128,000 University of Galway alumni worldwide. Stay connected to your alumni community! Join our social networks and update your details online.
-
Community Engagement
Community Engagement
At University of Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
June NUI Galway Researcher Leads Novel Computational Models for Personalised Medicine
NUI Galway Researcher Leads Novel Computational Models for Personalised Medicine
A person’s health is determined by their inherent genetic differences combined with lifestyles and the environments in which they live. This unique identity means that a “one size fits all” approach is no longer accepted as the best way to manage an individual’s health. There is a demand for new “personalised” approaches to better manage our health and to target therapies to achieve optimum health outcomes.
By combining and analysing information about our genome, with other clinical and diagnostic information, patterns can be identified that can help to determine our individual risk of developing disease, detect illness earlier and determine the most effective interventions to help improve health, be they medicines, lifestyle choices, or even simple changes in diet.
Researchers, led by Professor Ines Thiele, a Principal Investigator at APC Microbiome Ireland Science Foundation Ireland Research Centre, who is based at NUI Galway, have developed whole-body computational models - Harvey and Harvetta. These virtual humans represent whole-body metabolism, physiology, diet and the gut microbiome. These new models successfully predict known biomarkers of inherited metabolic diseases and enable exploration of potential metabolic interactions between humans and their gut microbiomes at a personal level.
Precision, or personalised, medicine requires realistic, mechanistic computational models that capture the complexity of the human representing each individual’s physiology, dietary habits, metabolism and microbiomes. Molecular biology has yielded great insight into the ‘parts list’ for human cells, but it remains challenging to integrate these parts into a virtual whole human body. The Virtual Human Physiome project has generated comprehensive computational models about the anatomy and physiology of human organs but has yet to be connected with molecular level processes and their underlying networks of genes, proteins, and biochemical reactions. Prof Thiele’s team tackled this challenge to develop the first whole-body, sex-specific, organ-resolved computational models of human metabolism, which mechanistically connect anatomy and physiology with molecular level metabolic processes. Their study is published today in the prestigious journal Molecular Systems Biology.
Harvey and Harvetta are virtual male and female human metabolic models, respectively, built from literature and data on human metabolism, anatomy and physiology as well as biochemical, metabolomic and proteomic data. They are anatomically interconnected as whole-body metabolic models, comprised of more than 80,000 biochemical reactions distributed over 26 organs and 6 types of blood cell. Moreover, they can be expanded to include gut microbial metabolism. These unique models enable generation of personalised whole-body metabolic models using an individual’s physiological, genomic, biochemical and microbiome data.
Generating personalised whole-body metabolic models is an interdisciplinary effort. The development of whole-body models of metabolism required the development of novel algorithms and software for constraint-based modelling of high-dimensional biochemical networks. “A whole-body model is generated by starting with a set of anatomically interconnected generic reconstructions of human metabolism”, says Assistant Professor Ronan Fleming, a co-author of the study from the Leiden Academic Centre for Drug Research, Leiden University. “This draft model had in excess of 300 thousand dimensions, which was then pared down to approximately 80 thousand organ-specific reactions using efficient algorithms and high-performance computing facilities.”
“Harvey and Harvetta will usher in a new era for research into causal host-microbiome relationships and greatly accelerate the development of targeted dietary and microbial intervention strategies” said Prof Ines Thiele, who lead the research. “These models could accelerate insights into pathways involved in sex-specific disease development and progression. Moreover, thanks to the ability to personalize the whole-body metabolic models with clinical, physiological, and omics data, they represent a significant step towards personalised, predictive modelling of dietary and drug interventions and drug toxicity, which lies at the heart of precision medicine.”
To view the full study visit https://doi.org/10.15252/msb.20198982
This study was funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 757922), the Luxembourg National Research Fund (FNR) through the ATTRACT programme (FNR/A12/01), the National Centre of Excellence in Research (NCER) on Parkinson’s disease, and the European Union’s Horizon 2020 research and innovation program under grant agreement No. 668738.
-Ends-